接受肝切除术患者的氨甲环酸应用:HeLiX随机临床试验
这项多中心随机临床试验在加拿大10个肝胆胰中心和美国的1个中心进行,纳入1384例因癌症相关指征接受肝切除术的患者,比较氨甲环酸与安慰剂。主要分析纳入1245例参与者,结果显示氨甲环酸组7天内红细胞输注率为16.3%,安慰剂组为14.5%,差异无统计学意义;氨甲环酸组并发症显著增多。
要点
- 氨甲环酸未减少肝切除术患者7天内红细胞输注(16.3% vs 14.5%,OR 1.15,95%CI 0.84-1.56,P=0.38)。
- 氨甲环酸组并发症显著多于安慰剂组(OR 1.28,95%CI 1.02-1.60,P=0.03)。
- 静脉血栓栓塞发生率两组无显著差异(OR 1.68,95%CI 0.95-3.07,P=0.08)。
核心结论
- 在因癌症相关指征接受肝切除术的患者中,氨甲环酸未减少出血或输血,但增加了围术期并发症。
研究设计与样本
- 多中心随机临床试验,比较氨甲环酸与安慰剂,于2014年12月1日至2022年11月8日在加拿大10个肝胆胰中心和美国的1个中心进行,随访90天。
- 参与者、临床医生和数据收集者对分组设盲;1384例因癌症相关指征接受肝切除术的患者符合入选标准并同意随机分组。
- 干预为麻醉诱导时开始给予氨甲环酸(1克推注后8小时内输注1克;n=619)或匹配安慰剂(n=626)。
- 主要分析纳入1245例参与者(平均年龄63.2岁;女性39.8%;结直肠肝转移诊断56.1%)。
主要发现
- 氨甲环酸组7天内红细胞输注发生率为16.3%(n=101),安慰剂组为14.5%(n=91),比值比1.15(95%CI 0.84-1.56;P=0.38),绝对差异2%(95%CI -2%至6%)。
- 术中测得出血量氨甲环酸组为817.3 mL,安慰剂组为836.7 mL(P=0.75);7天内总估计失血量氨甲环酸组为1504.0 mL,安慰剂组为1551.2 mL(P=0.38),两组相似。
- 接受氨甲环酸的患者并发症显著多于安慰剂组(比值比1.28,95%CI 1.02-1.60;P=0.03)。
- 静脉血栓栓塞无显著差异(比值比1.68,95%CI 0.95-3.07;P=0.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tranexamic acid reduces bleeding and blood transfusion in many types of surgery, but its effect in patients undergoing liver resection for a cancer-related indication remains unclear. OBJECTIVE: To determine whether tranexamic acid reduces red blood cell transfusion within 7 days of liver resection. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial of tranexamic acid vs placebo conducted from December 1, 2014, to November 8, 2022, at 10 hepatopancreaticobiliary sites in Canada and 1 site in the United States, with 90-day follow-up. Participants, clinicians, and data collectors were blinded to allocation. A volunteer sample of 1384 patients undergoing liver resection for a cancer-related indication met eligibility criteria and consented to randomization. INTERVENTIONS: Tranexamic acid (1-g bolus followed by 1-g infusion over 8 hours; n = 619) or matching placebo (n = 626) beginning at induction of anesthesia. MAIN OUTCOMES AND MEASURES: The primary outcome was receipt of red blood cell transfusion within 7 days of surgery. RESULTS: The primary analysis included 1245 participants (mean age, 63.2 years; 39.8% female; 56.1% with a diagnosis of colorectal liver metastases). Perioperative characteristics were similar between groups. Red blood cell transfusion occurred in 16.3% of participants (n = 101) in the tranexamic acid group and 14.5% (n = 91) in the placebo group (odds ratio, 1.15 [95% CI, 0.84-1.56]; P = .38; absolute difference, 2% [95% CI, -2% to 6%]). Measured intraoperative blood loss (tranexamic acid, 817.3 mL; placebo, 836.7 mL; P = .75) and total estimated blood loss over 7 days (tranexamic acid, 1504.0 mL; placebo, 1551.2 mL; P = .38) were similar between groups. Participants receiving tranexamic acid experienced significantly more complications compared with placebo (odds ratio, 1.28 [95% CI, 1.02-1.60]; P = .03), with no significant difference in venous thromboembolism (odds ratio, 1.68 [95% CI, 0.95-3.07]; P = .08). CONCLUSIONS AND RELEVANCE: Among patients undergoing liver resection for a cancer-related indication, tranexamic acid did not reduce bleeding or blood transfusion but increased perioperative complications. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02261415.
引用
- Karanicolas PJ, Lin Y, McCluskey SA, et al. Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial. JAMA. 2024. PMID: 39158894. doi:10.1001/jama.2024.11783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。